{"id":"olbetam","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea and vomiting","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Hydroxycarboxylic acid receptor 2"},"_scrapedAt":"2026-03-28T04:18:10.785Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T10:11:39.318933+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Hyperlipoproteinemia","diseaseId":"hyperlipoproteinemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06229678","phase":"EARLY_PHASE1","title":"Ketones, SGLT2, HFrEF","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-01-25","conditions":"Type2diabetes, Heart Failure With Reduced Ejection Fraction","enrollment":71},{"nctId":"NCT03338387","phase":"PHASE2","title":"Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia","status":"ENROLLING_BY_INVITATION","sponsor":"Charles University, Czech Republic","startDate":"2003-05-06","conditions":"Eating Disorder, Bulimia Nervosa","enrollment":24},{"nctId":"NCT03866512","phase":"NA","title":"Forearm Immobilization, Metabolic Health, and Muscle Loss","status":"COMPLETED","sponsor":"University of Exeter","startDate":"2019-05-10","conditions":"Healthy","enrollment":37},{"nctId":"NCT06317142","phase":"","title":"Glucose and Glycogen Dynamics in Prediabetes","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2024-02-20","conditions":"Pre Diabetes","enrollment":45},{"nctId":"NCT03804892","phase":"NA","title":"Can Brisk Walking Combined With Ingestion of a Lipid-lowering Drug Improve Fat Metabolism in Muscle?","status":"UNKNOWN","sponsor":"Liverpool John Moores University","startDate":"2019-10-01","conditions":"Pre Diabetes","enrollment":12},{"nctId":"NCT03809793","phase":"NA","title":"Can the Health Benefits of a Walking-based Exercise Programme be Enhanced by Co-ingestion of a Lipid-lowering Drug?","status":"COMPLETED","sponsor":"Liverpool John Moores University","startDate":"2020-01-06","conditions":"Pre-diabetes","enrollment":15},{"nctId":"NCT00759291","phase":"PHASE2, PHASE3","title":"The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2006-04-01","conditions":"Metabolic Syndrome","enrollment":40},{"nctId":"NCT01816165","phase":"PHASE3","title":"Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-06","conditions":"Type 1 Diabetes","enrollment":28},{"nctId":"NCT01580813","phase":"NA","title":"Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":13},{"nctId":"NCT02782208","phase":"NA","title":"Lipolytic Effects of GH in Hypopituitary Patients in Vivo","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-02-10","conditions":"Hypopituitarism, Insulin Resistance, Endocrine System Diseases","enrollment":9},{"nctId":"NCT02792621","phase":"NA","title":"Increasing Mitochondrial Function on Skeletal Muscle Performance in Older Men","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-11-08","conditions":"Impaired Mitochondrial Function, Muscle Performance","enrollment":16},{"nctId":"NCT03325491","phase":"NA","title":"Assessing the Effects of Increased Mitochondrial Function Exercise Training on Muscle Performance","status":"TERMINATED","sponsor":"University of Exeter","startDate":"2018-03-07","conditions":"Impaired Mitochondrial Function, Muscle Performance","enrollment":2},{"nctId":"NCT00153179","phase":"PHASE1, PHASE2","title":"Free Fatty Acids and Vascular Function in Subjects With Diabetes","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2005-09","conditions":"Type 2 Diabetes Mellitus","enrollment":40},{"nctId":"NCT02796950","phase":"NA","title":"The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-06","conditions":"Diabetes Mellitus Type 2","enrollment":8},{"nctId":"NCT01209416","phase":"NA","title":"The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2012-06","conditions":"Metabolism, Insulin Resistance, Hypopituitarism","enrollment":8},{"nctId":"NCT01980524","phase":"PHASE2, PHASE3","title":"The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":8},{"nctId":"NCT01488409","phase":"PHASE2","title":"Effects of Acipimox on Mitochondrial Function in Obesity","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-05","conditions":"Abdominal Obesity, Insulin Resistance, Hypertriglyceridemia","enrollment":39},{"nctId":"NCT01752348","phase":"NA","title":"Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals.","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2013-02","conditions":"Systemic Inflammatory Response Syndrome","enrollment":10},{"nctId":"NCT02256722","phase":"PHASE1","title":"In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT01299831","phase":"NA","title":"The Relationship Between Body Composition and Growth Hormone, SIRT Signaling, Protein Turnover and Insulin Sensitivity","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-01","conditions":"Healthy","enrollment":19},{"nctId":"NCT00246402","phase":"NA","title":"Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2002-09","conditions":"Insulin Resistance, Cardiovascular Diseases, Heart Diseases","enrollment":30},{"nctId":"NCT00943059","phase":"NA","title":"Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2, Cardiomyopathy, Dilated","enrollment":31},{"nctId":"NCT01260376","phase":"NA","title":"Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-04","conditions":"Diabetes, Obesity","enrollment":9},{"nctId":"NCT00549614","phase":"NA","title":"Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2007-10","conditions":"Heart Failure","enrollment":28},{"nctId":"NCT00449423","phase":"PHASE2","title":"Metabolic Modulation as Treatment in Acute Heart Failure","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2007-03","conditions":"Acute Heart Failure","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":13,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"Olbetam","genericName":"Olbetam","companyName":"University of Aarhus","companyId":"university-of-aarhus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":5,"withResults":2},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T10:11:39.318933+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}